Literature DB >> 627316

Calcium and secretin as provocative stimuli in the Zollinger-Ellison syndrome.

A A Mihas, B I Hirschowitz, R G Gibson.   

Abstract

The effects of calcium and secretin were studied in 8 patients with the Zollinger-Ellison syndrome and 18 patients with duodenal ulcer disease. Intravenous infusion of calcium gluconate produced marked increases in serum gastrin levels in the patients with Zollinger-Ellison syndrome (4,350 +/- 1,625 pg/mg) and very slight increases in the patients with duodenal ulcer disease (140 +/- 49 pg/ml). Secretin given as a single intravenous injection also induced marked elevations in serum gastrin in the group with the Zollinger-Ellison syndrome (4,063 +/- 1,990 pg/ml). By contrast, intravenous secretin resulted in a progressive fall in serum gastrin levels in the duodenal ulcer group (from 119 to 97 pg/mg). These results suggest that both stimuli are very useful dagnostic tools in discriminating between Zollinger-Ellison and non-Zollinger-Ellison patients. The secretin challenge test is felt to be superior to the calcium infusions because it is simpler, safer and very rarely produces false-negative or-positive results.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 627316     DOI: 10.1159/000198088

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  3 in total

1.  Secretin provocation in normal and duodenal ulcer subjects. Is the gastrin rise in Zollinger-Ellison syndrome paradoxic or exaggeration?

Authors:  C E Brady; S J Utts; J Dev
Journal:  Dig Dis Sci       Date:  1987-03       Impact factor: 3.199

2.  Serum gastrin levels in response to exogenous secretin in patients with duodenal ulcer--false positive response occurring in case of endoscopically active ulcer.

Authors:  K Shiratori; S Watanabe; T Takeuchi
Journal:  Gastroenterol Jpn       Date:  1982-04

3.  Comparison of four provocative tests for the diagnosis of gastrinoma.

Authors:  M E Romanus; J A Neal; W G Dilley; G S Leight; W M Linehan; R J Santen; J R Farndon; R S Jones; S A Wells
Journal:  Ann Surg       Date:  1983-05       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.